Literature DB >> 12639763

HRT does not improve urinary albumin excretion in postmenopausal diabetic women.

Patrick J Manning1, Wayne H F Sutherland, Anne R Allum, Sylvia A de Jong, Shirley D Jones.   

Abstract

The effect of 6 months combined, continuous hormone replacement therapy (HRT) with conjugated equine oestrogen (0.625 mg) and medroxyprogesterone acetate (2.5 mg) on albumin/creatinine ratio (ACR) was determined in postmenopausal diabetic women in a randomised, controlled study. Mean (interquartile range) change in plasma ACR was not (P=0.96) different in women receiving HRT [2 (-11, 21) mg/g, n=20] compared with those randomised to placebo [2 (-1, 14) mg/g, n=27]. Also, the proportion of women with microalbuminuria did not change (P=0.75) during HRT (baseline, 0.45; end of study, 0.53). Furthermore, several risk factors for microalbuminuria including systolic blood pressure (SBP), fasting blood glucose, glycated haemoglobin (HbA1c) and adiposity did not vary significantly during HRT. These data suggest that 6 months HRT does not reverse microalbuminuria caused by prolonged hyperglycaemia and other risk factors that underlie leakage of albumin into the urine in postmenopausal women with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639763     DOI: 10.1016/s0168-8227(02)00279-6

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  10 in total

1.  Dose-dependent toxic effects of high-dose estrogen on renal and cardiac injury in surgically postmenopausal mice.

Authors:  Xiaomei Meng; Xiangguo Dai; Tang-Dong Liao; Martin D'Ambrosio; Fangfei Wang; James J Yang; Xiao-Ping Yang
Journal:  Life Sci       Date:  2010-11-11       Impact factor: 5.037

2.  Sex Hormones and Measures of Kidney Function in the Diabetes Prevention Program Outcomes Study.

Authors:  Catherine Kim; Ana C Ricardo; Edward J Boyko; Costas A Christophi; Marinella Temprosa; Karol E Watson; Xavier Pi-Sunyer; Rita R Kalyani
Journal:  J Clin Endocrinol Metab       Date:  2019-04-01       Impact factor: 5.958

Review 3.  Sexual dimorphism in the aging kidney: differences in the nitric oxide system.

Authors:  Chris Baylis
Journal:  Nat Rev Nephrol       Date:  2009-06-02       Impact factor: 28.314

Review 4.  The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease.

Authors:  Sebastian Kummer; Gero von Gersdorff; Markus J Kemper; Jun Oh
Journal:  Pediatr Nephrol       Date:  2011-07-16       Impact factor: 3.714

5.  A cross-sectional and 10-year prospective study of postmenopausal estrogen therapy and blood pressure, renal function, and albuminuria: the Rancho Bernardo Study.

Authors:  Maple M Fung; Sameer Poddar; Ricki Bettencourt; Simerjot Kaur Jassal; Elizabeth Barrett-Connor
Journal:  Menopause       Date:  2011-06       Impact factor: 2.953

Review 6.  Sex, diabetes and the kidney.

Authors:  Christine Maric
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-14

7.  Post-menopausal hormone use and albuminuria.

Authors:  Emily L Schopick; Naomi D Fisher; Julie Lin; John P Forman; Gary C Curhan
Journal:  Nephrol Dial Transplant       Date:  2009-07-02       Impact factor: 5.992

8.  Hormone therapy and urine protein excretion: a multiracial cohort study, systematic review, and meta-analysis.

Authors:  Andrea G Kattah; Maria L G Suarez; Natasa Milic; Kejal Kantarci; Burcu Zeydan; Thomas Mosley; Stephen T Turner; Erin B Ware; Sharon L R Kardia; Vesna D Garovic
Journal:  Menopause       Date:  2018-06       Impact factor: 2.953

9.  Sex Hormone Status in Women With Chronic Kidney Disease: Survey of Nephrologists' and Renal Allied Health Care Providers' Perceptions.

Authors:  Sharanya Ramesh; Matthew T James; Jayna M Holroyd-Leduc; Stephen B Wilton; Ellen W Seely; David C Wheeler; Sofia B Ahmed
Journal:  Can J Kidney Health Dis       Date:  2017-10-27

10.  Older menarche age and short reproductive period linked to chronic kidney disease risk.

Authors:  Ji Hyun Noh; Hoseok Koo
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.